- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00449514
Tamoxifen Compared With Clomiphene Citrate for Women Who Had Thin Endometrium Women Under Clomiphene in a Previous Cycle
September 19, 2007 updated by: Shaare Zedek Medical Center
Prospective Randomized Study of Ovulation Induction Using Either Tamoxifen or Clomiphene Citrate for Women Who Had Thin Endometrium During Previous Treatment With Clomiphene Citrate
About 10-15% of all couples attempting to conceive will not become pregnant within one year.
Among those, the majority will have ovulatory dysfunction, mild male infertility or unexplained infertility.
The traditional first line therapy for those couples is ovulation induction or superovulation using clomiphene citrate.
Probably due to anti-estrogenic effects of this agent will, some patients will have a thin endometrium as measured by sonography at the time of ovulation.
This phenomenon may be associated with a lower chance to conceive.
Tamoxifen is a similar molecule that has been used to clomiphene citrate that has been shown to be equally effective to clomiphene in ovulation induction.
Preliminary observations showed that tamoxifen does not cause a negative effect on the endometrium as compared with clomiphene, and may increase the chance to conceive in those patients who have a thin endometrium under clomiphene.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Jerusalem, Israel
- Recruiting
- Shaare-Zedek Medical Center
-
Principal Investigator:
- Avi Tsafrir, MD
-
Contact:
- Avi Tsafrir, MD
- Phone Number: +972-508573805
- Email: avits@szmc.org.il
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 31 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Primary or secondary infertility due to:
- Ovulatory dysfunction
- Mild male infertility
- Unexplained infertility
- Endometrium < 6 mm at time of hCG during previous treatment with clomiphene citrate
- Age 18-35
Exclusion Criteria:
- Serious adverse effects under clomiphene citrate or known sensitivity to either tamoxifen or clomiphene citrate
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Pregnancy rate
|
|
delivery rate
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
endometrium thickness
|
|
percentage of ovulation
|
|
number of follicles
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Avi Tsafrir, MD, Department of Obstetrics and Gynecology, Shaare-Zedek Medical Center, Jerusalem, Israel
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2007
Study Registration Dates
First Submitted
March 18, 2007
First Submitted That Met QC Criteria
March 19, 2007
First Posted (Estimate)
March 20, 2007
Study Record Updates
Last Update Posted (Estimate)
September 20, 2007
Last Update Submitted That Met QC Criteria
September 19, 2007
Last Verified
May 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infertility
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Bone Density Conservation Agents
- Estrogen Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Tamoxifen
- Clomiphene
- Enclomiphene
- Zuclomiphene
Other Study ID Numbers
- tamoxi vs clomiphene.CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.